<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578135</url>
  </required_header>
  <id_info>
    <org_study_id>GHSGA-1757</org_study_id>
    <nct_id>NCT01578135</nct_id>
  </id_info>
  <brief_title>French National Registry of Children Born Small for Gestational Age Treated With Somatropin</brief_title>
  <official_title>French National Longitudinal Prospective Follow-up of Children Born Small for Gestational Age and Treated With Norditropin SimpleXx (French Health Authorities Commitment)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Europe. The aim of the study is to describe the patient population
      and therapeutic practices (study phase I), assess efficacy on growth and adult height and
      assess tolerance of somatropin (Norditropin® SimpleXx®) (study phase II)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 19, 2007</start_date>
  <completion_date type="Anticipated">April 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Growth in height</measure>
    <time_frame>6 months after inclusion into registry and then annually until adult height is reached</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure: Systolic and diastolic</measure>
    <time_frame>6 months after inclusion into registry and then annually until adult height is reached</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone age</measure>
    <time_frame>6 months after inclusion into registry and then annually until adult height is reached</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin-Like Growth Factor 1 (IGF-1)</measure>
    <time_frame>6 months after inclusion into registry and then annually until adult height is reached</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Growth Disorder</condition>
  <condition>Small for Gestational Age</condition>
  <arm_group>
    <arm_group_label>Phase I</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
    <description>Patients are to fill in a questionnaire at inclusion in registry</description>
    <arm_group_label>Phase I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
    <description>Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached</description>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Phase I: All patients born SGA treated with Norditropin® SimpleXx® (somatropin) whether
        they were previously treated with another growth hormone for this indication or not from
        the 29th of April 2005 until 29th of April 2010.

        Phase II: Sub-population randomly selected (every 5th patient being included in registry in
        study phase I).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Born small for gestational age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Paris La Défense</city>
        <zip>92936</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Growth Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

